Patients with malignant pleural mesothelioma (MPM) now have new hope, with the first FDA-approved treatment in more than 15 years. Healthcare providers at Goshen Center for Cancer Care are certified to prescribe a wearable and portable medical device which delivers NovoTTF-100L to treat this cancer. Goshen Center for Cancer Care is one of the first in the country to offer this innovative treatment.
“Some people with this type of cancer are not candidates for surgery, and approved, non-surgical treatments are very limited,” said Dr. Houman Vaghefi, Director of Radiation Oncology at Goshen Center for Cancer Care. “We are thrilled that with NovoTTF-100L, we can now offer the latest-approved therapy as part of a combination treatment, giving another, much-needed option to patients and their families.”
NovoTTF-100L is a non-invasive, antimitotic cancer treatment that delivers Tumor Treating Fields to the region of a tumor. Tumor Treating Fields therapy, which uses electric fields tuned to specific frequencies, is designed to specifically target and directly disrupt dividing tumor cells, inhibiting tumor growth and possibly causing affected cancer cells to die while sparing normal, healthy cells.
“Goshen Center for Cancer Care continues to lead the region with innovative care for patients and this announcement is yet another example of the tremendous impact they are making each and every day,” stated Randy Christophel, President and CEO of Goshen Health. “We are proud to provide world-class care throughout our community and well beyond.”
NovoTTF-100L now available at Goshen Center for Cancer Care for the treatment of malignant pleural mesothelioma (MPM).